Cover Image
市場調查報告書

International Stem Cell Corporation : 產品平台分析

International Stem Cell Corporation - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 308910
出版日期 內容資訊 英文 23 Pages
訂單完成後即時交付
價格
Back to Top
International Stem Cell Corporation : 產品平台分析 International Stem Cell Corporation - Product Pipeline Review - 2015
出版日期: 2015年08月12日 內容資訊: 英文 23 Pages
簡介

International Stem Cell Corporation 是為了強化再生醫療領域而開發單為生殖幹細胞技術的生物科技企業。該公司同時也正在開發眼睛、神經系統,肝臟疾病的治療藥。

本報告提供International Stem Cell Corporation的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

International Stem Cell Corporation的基本資料

  • International Stem Cell Corporation概要
  • 主要資訊
  • 企業資料

International Stem Cell Corporation:R&D概要

  • 主要的治療範圍

International Stem Cell Corporation:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

International Stem Cell Corporation:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

International Stem Cell Corporation:藥物簡介

  • ISC-hpNSC
  • CytoCor
  • Stem Cell Therapy for Age Related Macular Degeneration and Retinitis Pigmentosa
  • Stem Cell Therapy for Alpha-Antitrypsin Deficiency and Crigler-Najjar Syndrome

International Stem Cell Corporation:開發平台分析

  • 各分子類型

International Stem Cell Corporation:最近的開發平台趨勢

International Stem Cell Corporation:總公司和子公司的所在地

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07512CDB

Summary

Global Markets Direct's, 'International Stem Cell Corporation - Product Pipeline Review - 2015', provides an overview of the International Stem Cell Corporation's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of International Stem Cell Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of International Stem Cell Corporation including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of International Stem Cell Corporation's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the International Stem Cell Corporation's pipeline products

Reasons to buy

  • Evaluate International Stem Cell Corporation's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of International Stem Cell Corporation in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the International Stem Cell Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of International Stem Cell Corporation and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of International Stem Cell Corporation
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of International Stem Cell Corporation and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • International Stem Cell Corporation Snapshot
    • International Stem Cell Corporation Overview
    • Key Information
    • Key Facts
  • International Stem Cell Corporation - Research and Development Overview
    • Key Therapeutic Areas
  • International Stem Cell Corporation - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • International Stem Cell Corporation - Pipeline Products Glance
    • International Stem Cell Corporation - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • International Stem Cell Corporation - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • International Stem Cell Corporation - Drug Profiles
    • ISC-hpNSC
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CytoCor
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Stem Cell Therapy for Age Related Macular Degeneration and Retinitis Pigmentosa
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Stem Cell Therapy for Alpha-Antitrypsin Deficiency and Crigler-Najjar Syndrome
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • International Stem Cell Corporation - Pipeline Analysis
  • International Stem Cell Corporation - Pipeline Products by Molecule Type
  • International Stem Cell Corporation - Recent Pipeline Updates
  • International Stem Cell Corporation - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • International Stem Cell Corporation, Key Information
  • International Stem Cell Corporation, Key Facts
  • International Stem Cell Corporation - Pipeline by Indication, 2015
  • International Stem Cell Corporation - Pipeline by Stage of Development, 2015
  • International Stem Cell Corporation - Monotherapy Products in Pipeline, 2015
  • International Stem Cell Corporation - Phase I, 2015
  • International Stem Cell Corporation - Preclinical, 2015
  • International Stem Cell Corporation - Pipeline by Molecule Type, 2015
  • International Stem Cell Corporation - Recent Pipeline Updates, 2015
  • International Stem Cell Corporation, Other Locations
  • International Stem Cell Corporation, Subsidiaries

List of Figures

  • International Stem Cell Corporation - Pipeline by Top 10 Indication, 2015
  • International Stem Cell Corporation - Pipeline by Stage of Development, 2015
  • International Stem Cell Corporation - Monotherapy Products in Pipeline, 2015
  • International Stem Cell Corporation - Pipeline by Top 10 Molecule Type, 2015
Back to Top